Cargando…

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis. Therefore, we hypothesize that transthyretin cardiac amyloidosis patients have worse atrial function. Purpose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Versteylen, Mathijs O., Brons, Maaike, Teske, Arco J., Oerlemans, Marish I. F. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330560/ https://www.ncbi.nlm.nih.gov/pubmed/35892668 http://dx.doi.org/10.3390/biomedicines10081768

Ejemplares similares

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2022)

Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study
por: Palmer, Cassady, et al.
Publicado: (2022)

Evidence of Concurrent Light Chain and Transthyretin Cardiac Amyloidosis in 2 Patients
por: Donnelly, Joseph P., et al.
Publicado: (2020)

Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis
por: Miyamoto, Masakazu, et al.
Publicado: (2023)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
por: Bandera, Francesco, et al.
Publicado: (2022)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience
por: Brons, Maaike, et al.
Publicado: (2022)

Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Transthyretin cardiac amyloidosis: an update on diagnosis and treatment
por: Yamamoto, Hiroyuki, et al.
Publicado: (2019)

The Role of Imaging in Diagnosing Transthyretin Cardiac Amyloidosis
por: Chaaban, Nourhan, et al.
Publicado: (2021)

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Spontaneous intramyocardial haematoma in transthyretin cardiac amyloidosis
por: Parizher, Gary, et al.
Publicado: (2022)

Risk stratification in transthyretin-related cardiac amyloidosis
por: Scirpa, Riccardo, et al.
Publicado: (2023)

Multimodality Imaging for Diagnosing Transthyretin Cardiac Amyloidosis
por: Palot Manzil, Fathima Fijula, et al.
Publicado: (2023)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2020)

Step‐by‐step typing for the accurate diagnosis of concurrent light chain and transthyretin cardiac amyloidosis
por: Moriyama, Hidenori, et al.
Publicado: (2022)

Cardiogenic Shock Due to Atrial Arrhythmia as the Initial Presentation of Transthyretin Cardiac Amyloidosis
por: Schneider, Svenja M., et al.
Publicado: (2022)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019)

Analysis of disease progression in patients with transthyretin cardiac amyloidosis
por: Gilmore, Julian D, et al.
Publicado: (2015)

Ruptured Bullae: A Case of Transthyretin Cardiac Amyloidosis
por: Dayco, John, et al.
Publicado: (2021)

How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage
por: Izumiya, Yasuhiro, et al.
Publicado: (2020)

Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease
por: Perfetto, Federico, et al.
Publicado: (2022)

Concurrent Waldenstrom Macroglobulinemia and Mutant Transthyretin Cardiac Amyloidosis
por: Qian, Xiaoxiao, et al.
Publicado: (2022)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
por: Ridouani, Fourat, et al.
Publicado: (2018)

Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome
por: Nitsche, Christian, et al.
Publicado: (2020)

Trajectory of left ventricular geometry and diastolic dysfunction in hereditary transthyretin cardiac amyloidosis
por: Akatsuka, Tatsuya, et al.
Publicado: (2021)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment
por: Wu, Yuan‐Kun (Aden), et al.
Publicado: (2022)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
por: Maurer, Mathew S., et al.
Publicado: (2022)

Multimodality imaging of simultaneous occurrence of cardiac transthyretin amyloidosis and cardiac sarcoidosis
por: Elchinova, Elena, et al.
Publicado: (2022)

Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
por: Zampiccoli, Emanuel, et al.
Publicado: (2022)

Stroke risk and atrial mechanical dysfunction in cardiac amyloidosis
por: Ballantyne, Brennan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1clgljgqm7pufstrkuafkhsl5j